Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881236 | 0.90 | PDE3B (0.45) | CHEK1 | |
| SCHEMBL6487209 | 0.82 | TSHR (0.47) | TSHRMAPK1ALDH1A1GAAHSD17B10 | |
| SCHEMBL15613194 | 0.80 | EGFR (0.46) | TSHRCYP2D6CHEK1AXLSRC | |
| SCHEMBL31016533 | 0.78 | CHEK1 (0.55) | TSHRCYP2D6CHEK1TDP1KDM4E | |
| SCHEMBL2836782 | 0.77 | PDE3B (0.61) | TSHRMAPK1SRCALDH1A1GAA | |
| SCHEMBL7094017 | 0.74 | SYK (0.52) | TSHRCYP2D6CHEK1KDM4EMAPK1 | |
| SCHEMBL3280907 | 0.72 | CYP2D6 (0.46) | TSHRCYP2D6CHEK1TDP1KDM4E | |
| SCHEMBL27958219 | 0.71 | CYP2D6 (0.66) | TSHRCYP2D6CHEK1TDP1KDM4E | |
| SCHEMBL6031474 | 0.71 | EGFR (0.50) | — | |
| SCHEMBL6433993 | 0.70 | SRC (0.56) | TSHRCYP2D6CHEK1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | claimed |
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | disclosed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | CYP3A7, CYP3A5, CYP4B1 | TSHR 4724/4885CYP2D6 16/4885CHEK1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.